Chad Broome-Webster, MD
Cardiovascular Disease · Orange City, FLNPI 1669430732
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $659 and has fallen 75.6% since, to $161 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in FL, where the typical reported total is $2,774.
Across 144 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$501
- Merck$398
- Abbott$378
- Cvrx, Inc.$351
- Boehringer Ingelheim$234
- Amgen$164
- plus $758 from 15 others
Across 69 payments — averaging $633.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$18K
- Boehringer Ingelheim International GmbH$14K
- Sanofi US Services Inc.$8K
- Boehringer Ingelheim Pharma GmbH & Co.kg$5K
What the payments were for
- Food & beverage$2,76399%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 28 | $501 |
| Merck | 26 | $398 |
| Abbott | 16 | $378 |
| Cvrx, Inc. | 17 | $351 |
| Boehringer Ingelheim | 10 | $234 |
| Amgen | 10 | $164 |
| Medtronic(2 entities) | 2 | $151 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $146 |
| Johnson & Johnson | 7 | $123 |
| Kestra Medical Technology Services, Inc. | 3 | $63 |
| Impulse Dynamics (USA) Inc. | 1 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Bardy Diagnostics, Inc. | 3 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $35 |
| Abiomed | 1 | $29 |
| Atricure, Inc. | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Baxter Healthcare | 1 | $13 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HawkOne$129
How this compares
$2,785 in reported general payments places this provider in the 50th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 534 | $496,108 |
| EntrestoSacubitril/Valsartan | 211 | $182,128 |
| XareltoRivaroxaban | 216 | $159,004 |
| JardianceEmpagliflozin | 119 | $92,780 |
| BrilintaTicagrelor | 61 | $46,704 |
| MultaqDronedarone Hcl | 29 | $28,754 |
| FarxigaDapagliflozin Propanediol | 39 | $26,846 |
| Repatha SureclickEvolocumab | 26 | $19,168 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 68 | $10,672 |
| Metoprolol Succinate | 727 | $9,110 |
| Midodrine Hcl | 103 | $7,585 |
| Isosorbide Dinitrate | 181 | $5,643 |
| Ranolazine ErRanolazine | 62 | $4,982 |
| Amiodarone Hcl | 161 | $4,659 |
| Bumetanide | 100 | $4,175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $501 | $182,128211 claims |
| Johnson & JohnsonXarelto | $123 | $159,004216 claims |
| Boehringer IngelheimJardiance | $234 | $92,780119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Orange City
- Sameer ChadhaOrange City$132K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.